Fisher S G, Benitez-Bribiesca L, Nindl I, Stockfleth E, Muller M, Wolf H, Perez-Garcia F, Guzman-Gaona J, Gutierrez-Delgado F, Irvin W, Gissmann L
Department of Obstetrics and Gynecology, Loyola University Medical Center, Maywood, Illinois 60153, USA.
Gynecol Oncol. 1996 Apr;61(1):73-8. doi: 10.1006/gyno.1996.0099.
Previous investigators have reported higher HPV type 16 antibody positivity among cervical cancer patients than among healthy women. The objective of this study was to determine the association of HPV 16 antibody levels with the stage of cervical cancer.
Pretreatment tumor biopsies and sera were obtained from 137 newly diagnosed cervical cancer patients residing in Mexico. Using peptide ELISA and radioimmunoprecipitation assay (RIPA), HPV 16 E6- and E7-specific antibodies were measured.
By ELISA, elevated antibody titers to HPV 16 E6 and E7 were detected in 16.8 and 32.8% of the women, respectively. While sera positivity did not differ by disease stage, the mean absorbance in the E7-positive sera was 0.42, 0.62, 0.91, and 0.81 for stages I to IV, respectively. Using RIPA, anti-E6 and E7 positivity was demonstrated in 46.7 and 38.7% of the females, respectively. Although no difference across disease stage was detected for E6, increasing proportions of positivity to E7 with stage of disease was detected. The rates for increasing disease stage were 0.14, 0.37, 0.40, and 0.67. Sera from the 6-month postradiation follow-up examinations of a small group of patients demonstrated a statistically significant decrease in antibody positivity from pretreatment positivity to HPV 16 E6 (n = 14; P = 0.01) and HPV 16 E7 (n = 20; P = 0.0001) using ELISA.
These data suggest that HPV 16 E7 antibody positivity may be associated with stage of cervical cancer. Such immune parameters may be applicable to disease staging, monitoring of recurrence and, perhaps, diagnosis. Further investigation into the relationship of HPV 16 E6 and E7 antibodies with stage of cervical cancer and response to therapy is warranted.
既往研究人员报告称，宫颈癌患者中16型人乳头瘤病毒（HPV）抗体阳性率高于健康女性。本研究的目的是确定HPV 16抗体水平与宫颈癌分期之间的关联。
从居住在墨西哥的137例新诊断宫颈癌患者中获取治疗前肿瘤活检组织和血清。采用肽酶联免疫吸附测定（ELISA）和放射免疫沉淀测定（RIPA）检测HPV 16 E6和E7特异性抗体。
通过ELISA检测，分别在16.8%和32.8%的女性中检测到HPV 16 E6和E7抗体滴度升高。虽然血清阳性率在不同疾病分期无差异，但I至IV期E7阳性血清的平均吸光度分别为0.42、0.62、0.91和0.81。采用RIPA检测，分别在46.7%和38.7%的女性中检测到抗E6和E7阳性。虽然E6在不同疾病分期未检测到差异，但随着疾病分期的增加，E7阳性比例增加。疾病分期增加的比例分别为0.14、0.37、0.40和0.67。一小部分患者放疗后6个月随访检查的血清显示，使用ELISA检测，HPV 16 E6（n = 14；P = 0.01）和HPV 16 E7（n = 20；P = 0.0001）抗体阳性率从治疗前阳性率显著下降。
这些数据表明，HPV 16 E7抗体阳性可能与宫颈癌分期有关。此类免疫参数可能适用于疾病分期、复发监测，或许还适用于诊断。有必要进一步研究HPV 16 E6和E7抗体与宫颈癌分期及治疗反应之间的关系。
